LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 33 of 66
Next
>>
>
801 to 825 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Neratinib	180619_MC_12	15285	0.0224	83	262	13	16	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_9	345	0.0221	635.9	71.1	15071	356.7	0.0231	-0.00100	1.0062
Neratinib	180619_MC_10	14470	0.0243	51	302	5	15	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_1	353	0.0238	635.9	71.1	15071	356.7	0.0231	0.00074	0.9823
Neratinib	180619_MC_10	14982	0.0217	57	269	9	8	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_2	326	0.0213	635.9	71.1	15071	356.7	0.0231	-0.00178	0.9974
Neratinib	180619_MC_10	12994	0.0204	37	229	13	12	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_3	266	0.0201	635.9	71.1	15071	356.7	0.0231	-0.00301	0.9361
Neratinib	180619_MC_11	13907	0.0220	53	254	4	21	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_4	307	0.0216	635.9	71.1	15071	356.7	0.0231	-0.00148	0.9651
Neratinib	180619_MC_11	15328	0.0249	84	299	8	16	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_5	383	0.0244	635.9	71.1	15071	356.7	0.0231	0.00130	1.0074
Neratinib	180619_MC_11	14087	0.0210	59	238	11	4	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_6	297	0.0206	635.9	71.1	15071	356.7	0.0231	-0.00243	0.9706
Neratinib	180619_MC_12	15061	0.0240	88	276	4	7	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_7	364	0.0236	635.9	71.1	15071	356.7	0.0231	0.00052	0.9997
Neratinib	180619_MC_12	15406	0.0261	95	310	4	16	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_8	405	0.0256	635.9	71.1	15071	356.7	0.0231	0.00254	1.0096
Neratinib	180619_MC_12	15469	0.0246	76	307	6	7	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_9	383	0.0242	635.9	71.1	15071	356.7	0.0231	0.00109	1.0114
Neratinib	180619_MC_10	12954	0.0183	39	199	6	9	Neratinib	0.00998	treatment	72	2	MCF10A-GM_1	238	0.0180	635.9	71.1	15071	356.7	0.0231	-0.00503	0.9348
Neratinib	180619_MC_10	14145	0.0197	65	215	7	21	Neratinib	0.00998	treatment	72	2	MCF10A-GM_2	280	0.0194	635.9	71.1	15071	356.7	0.0231	-0.00366	0.9724
Neratinib	180619_MC_10	13336	0.0184	41	205	14	20	Neratinib	0.00998	treatment	72	2	MCF10A-GM_3	246	0.0181	635.9	71.1	15071	356.7	0.0231	-0.00496	0.9471
Neratinib	180619_MC_11	15129	0.0224	65	276	3	9	Neratinib	0.00998	treatment	72	2	MCF10A-GM_4	341	0.0220	635.9	71.1	15071	356.7	0.0231	-0.00103	1.0017
Neratinib	180619_MC_11	15596	0.0242	58	321	8	7	Neratinib	0.00998	treatment	72	2	MCF10A-GM_5	379	0.0237	635.9	71.1	15071	356.7	0.0231	0.00065	1.0150
Neratinib	180619_MC_11	14264	0.0187	40	228	14	14	Neratinib	0.00998	treatment	72	2	MCF10A-GM_6	268	0.0184	635.9	71.1	15071	356.7	0.0231	-0.00463	0.9760
Neratinib	180619_MC_12	15391	0.0308	148	331	5	5	Neratinib	0.00998	treatment	72	2	MCF10A-GM_7	479	0.0302	635.9	71.1	15071	356.7	0.0231	0.00711	1.0092
Neratinib	180619_MC_12	15724	0.0263	129	288	9	12	Neratinib	0.00998	treatment	72	2	MCF10A-GM_8	417	0.0258	635.9	71.1	15071	356.7	0.0231	0.00276	1.0187
Neratinib	180619_MC_12	14831	0.0199	78	218	14	22	Neratinib	0.00998	treatment	72	2	MCF10A-GM_9	296	0.0196	635.9	71.1	15071	356.7	0.0231	-0.00351	0.9930
Neratinib	180619_MC_10	9675	0.0215	47	162	5	8	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_1	209	0.0211	635.9	71.1	15071	356.7	0.0231	-0.00193	0.8150
Neratinib	180619_MC_10	9684	0.0207	46	155	6	12	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_2	201	0.0203	635.9	71.1	15071	356.7	0.0231	-0.00274	0.8154
Neratinib	180619_MC_10	10194	0.0211	61	155	7	18	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_3	216	0.0207	635.9	71.1	15071	356.7	0.0231	-0.00233	0.8359
Neratinib	180619_MC_11	11686	0.0209	80	166	4	5	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_4	246	0.0206	635.9	71.1	15071	356.7	0.0231	-0.00246	0.8916
Neratinib	180619_MC_11	11711	0.0271	59	260	5	10	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_5	319	0.0265	635.9	71.1	15071	356.7	0.0231	0.00344	0.8925
Neratinib	180619_MC_11	12918	0.0222	73	215	13	3	Neratinib	0.031603333	treatment	72	2	MCF10A-GM_6	288	0.0218	635.9	71.1	15071	356.7	0.0231	-0.00127	0.9336

|<
<<
Previous
Page 33 of 66
Next
>>
>
801 to 825 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)